Analytical Data
-
Gene name
CYP2A6
- Application
-
Alternative Names
1,4-cineole 2-exo-monooxygenase (CYPIIA6) (Coumarin 7-hydroxylase) (Cytochrome P450 IIA3) (Cytochrome P450(I)) (CYP2A3)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11509
-
Expression Region
29-494aa
-
Molecular Weight
60.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2A6 is a prominent member of the cytochrome P450 family, playing a crucial role in the metabolism of various compounds, including nicotine and certain therapeutic drugs. Its significance in pharmacokinetics and drug interactions has led to extensive research in understanding its enzymatic functions and genetic variations among individuals. Genetic polymorphisms in CYP2A6 can result in diverse metabolic phenotypes, influencing smoking behavior and susceptibility to nicotine dependence, as well as varied responses to medications that are CYP2A6 substrates. Consequently, creating recombinant CYP2A6 proteins has become a valuable tool for investigating its enzymatic mechanisms, substrate specificities, and potential inhibitors. The expression and purification of recombinant CYP2A6 allow researchers to study its interactions with different ligands and to better predict the implications of genetic variations in drug metabolism. Additionally, insights gained from recombinant CYP2A6 studies contribute to advancements in personalized medicine, as understanding individual differences in drug metabolism can enhance therapeutic efficacy and minimize adverse effects. As such, the characterization of this enzyme through recombinant technologies is vital for both pharmacological research and the development of tailored therapeutic strategies.
